You’re exploring OKUR as your free preview. Sign up free for 3 full 5D deep-dives a month, or start a 14-day Pro trial for unlimited access to more than 3,000 US-listed stocks - no credit card.

OnKure Therapeutics, Inc.· OKUR

🇺🇸 US · MicroBroad USNASDAQ

Healthcare Biotechnology Website

Price: $2.52
Day: -2.33%
Mkt Cap: $102.05M
52W Range: $2.01 – $5.38
Volume: 240.9K
Beta: 0.30

D35D Framework

Valuation Analysis

Intrinsic-value engines paired with peer-anchored multiples.

Valuation: 4.0 / 5 (Below estimate); at $2.52 the price is 62% below the estimate of $7, which rests on market evidence only (no valuation model)
Estimates: sector peers $7 (241 companies), own 10-year history $4 (not used without a model)
Multiples: EV/EBITDA 1.1x vs sector median 7.0x

Blog

Valuation Assessment

OKUR Valuation Summary

How sector peers value it. With no valuation model behind it, the estimate rests on market evidence only

Overall valuation

4.0/5

Below estimate

Market only · blended estimate

$7+100%+

With no valuation model behind it, the estimate rests on market evidence only: the value implied by sector peers. The price is 62% below that estimate. Without a model to check it against, the score is held between 2 and 4 and the stock's own history is shown but not used.Last updated October 26, 2026.

Valuation Multiples

Per-metric breakdown of how OKUR is priced relative to its sector peers, its own 10-year history, and analyst forward estimates.

Valuation context: This company is currently unprofitable with negative EBITDA. P/E and EV/EBITDA aren't meaningful; focus on EV/FCF and FCF Yield in the primary grid, plus revenue multiples (P/S, EV/Sales) in the expanded section.

What sector peers imply

Value if it traded at the sector-median multiple

What its own history implies

Value if it traded at its own 10-year median multiple

How the Multiples lens works

Five primary multiples surface the headline call; five additional multiples sit one click deeper for context.

Valuation multiples compare a company's market price to its financial fundamentals. The primary grid covers both the equity perspective (P/E, PEG, FCF Yield) and the enterprise value perspective (EV/EBITDA, EV/FCF) so you see how the market prices the company two ways simultaneously.

Price-based multiples use market cap and reflect what equity investors pay. EV-based multiples include debt and are better for comparing companies with different capital structures. The expanded section below adds P/B, P/S, P/FCF, EV/EBIT, and EV/Sales for additional perspective.

Learn more about the 5D valuation methodology

Valuation Analysis

Intrinsic-value engines paired with peer-anchored multiples.

Valuation: 4.0 / 5 (Below estimate); at $2.52 the price is 62% below the estimate of $7, which rests on market evidence only (no valuation model)

Estimates: sector peers $7 (241 companies), own 10-year history $4 (not used without a model)

Multiples: EV/EBITDA 1.1x vs sector median 7.0x

OnKure Therapeutics, Inc.· OKUR

Valuation Analysis

Valuation Multiples

Additional valuation multiples5 more metrics: P/B Ratio, P/S Ratio, P/FCF, EV/EBIT, EV/Sales

How implied prices are calculated

Primary multiples primer

Search stocks

Valuation Analysis

Valuation Multiples

Additional valuation multiples5 more metrics: P/B Ratio, P/S Ratio, P/FCF, EV/EBIT, EV/Sales

How implied prices are calculated

Primary multiples primer